Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 30, 2023
Emerging Company Profile
Mysthera: restoring immune balance via PIM kinases
Basel-based company aims to dial down autoimmunity without shutting off helpful immune responses with $3.5M from Forty51
BioCentury | Aug 22, 2023
Finance
Aug. 22 Quick Takes: Forty51-backed Mysthera launches to development autoimmune therapies
Plus: FDA lifts hold on Fulcrum’s trial and more, panel to discuss Geron’s imetelstat
BioCentury | Aug 11, 2020
Finance
AI play Atomwise to build internal pipeline with $123M series B
After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its
BioCentury | Nov 15, 2019
Financial News
Atomwise JV raises $14.5M series A to advance AI-discovered candidates
Items per page:
1 - 5 of 5